HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target

Benzinga · 03/18 10:51
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.